패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Entera Bio Ltd. 3 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Kalpit Patel	B. Riley Securities, Inc.
null null	CG Capital
Raghuram Selvaraju	H.C. Wainwright & Co.

Entera Bio 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Recent updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus EPS estimates fall by 22%

New major risk - Financial position

New minor risk - Share price stability

Entera Bio Ltd. Announces New Comparative Pharmacological Data for its Investigational Agent EB613 Vs. Forteo® Selected for Presentation at ASBMR

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Shareholder dilution

Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Third quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 3Q 2022)

Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program

Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting

New minor risk - Share price stability

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

First half 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1H 2022)

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus revenue estimates decrease by 97%, EPS upgraded

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

No longer forecast to breakeven

Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Price target decreased by 11% to US$6.00

Entera Bio Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Insufficient new directors

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio Ltd. Announces Fda Agreement for A Single Phase 3 Clinical Trial to Support an NDA for Eb613 for the Treatment of Osteoporosis

Entera Bio Ltd. Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Price target increased to US$7.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Sep 07, 2022

Entera Bio Ltd. Announces Executive Changes

Insufficient new directors

Entera Bio Ltd. Announces Departure of Dr. Phillip Schwartz, President of Research & Development to Pursue Outside Opportunities

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Entera Bio Ltd. Announces Appointment of Miranda Toledano as Chief Business Officer and Head of Corporate Strategy

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$6.75

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Entera Bio Ltd. to Report Fiscal Year 2021 Results on Mar 08, 2022

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Entera Bio Announces Successful EB613 End-Of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (Bone Mineral Density) as the Primary Endpoint

Consensus forecasts updated

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.086 loss per share (vs US$0.089 loss in 3Q 2020)

Price target decreased to US$11.00

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow